Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer — VicTORia

Her2-negative Metastatic Breast Cancer Clinical Trial

Official title:
Randomized Phase II Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer

Status Completed

Clinical Trial Summary

The purpose of this study is Examination of the superiority of a combination of vinorelbine with the mTOR Inhibitor Everolimus vs. vinorelbine monotherapy for second-line treatment in advanced breast cancer.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Breast Neoplasms
Her2-negative Locally Advanced Breast Cancer
Her2-negative Metastatic Breast Cancer

Clinical Trial Details

NCT number	NCT01520103
Study type	Interventional
Source	AIO-Studien-gGmbH
Contact
Status	Completed
Phase	Phase 2
Start date	January 2012
Completion date	October 31, 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03430518` - Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer	Phase 1
Completed	`NCT01619111` - DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs	Phase 3
Completed	`NCT05261269` - A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer	Phase 1
Completed	`NCT02605915` - Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer	Phase 1
Recruiting	`NCT05362760` - Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management	Phase 4
Recruiting	`NCT04720729` - Chemotherapy Monitoring by ctDNA in HER2- Metastatic Breast Cancer	Phase 2